Giovan Giuseppe Di Costanzo, MD, Cardarelli Hospital, discusses a scoring system to predict the effectiveness of sorafenib (Nexavar) in hepatocellular carcinoma (HCC).

The scoring system was constructed to improve the therapeutic strategy for HCC, states Di Constanzo. For patients with advanced HCC the only approved treatment remains to be sorafenib, which is not effective in all patients.

There have been many studies aimed towards investigating ways to determine which patients will see positive results with sorafenib, states Di Costanzo.

Giovan Giuseppe Di Costanzo, MD

Articles

Dr. Di Costanzo on the Effectiveness of Sorafenib in HCC